Indoco Remedies Limited
Indoco Remedies announced the slump sale of its Ophthalmic Division to Sunways (India) Private Limited for a cash consideration of Rs. 110 crore. This strategic move aims to enable the company to focus on its core therapeutic areas.
May 01 2026 14:05:00
Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
Indoco Remedies has divested its Ophthalmic Division to Sunways (India) Private Limited for a consideration of Rs. 110 crore. This strategic move aims to enable the company to focus on its core therapeutic areas.
Apr 30 2026 19:04:00
Indoco Remedies Limited
Indoco Remedies divested its ophthalmic business division to Sunways (India) Private Limited for Rs. 110 crore. This strategic move allows Indoco to focus on its core therapeutic areas.
Apr 30 2026 19:04:00
Indoco Remedies Limited
Indoco Remedies Limited approved the transfer of its ophthalmic business in India and Africa to Sunways (India) Private Limited. This strategic move aims to sharpen Indoco's focus on core therapeutic areas with higher potential.
Apr 30 2026 19:04:00
Indoco Remedies Limited
Indoco Remedies Limited's Board approved the slump sale of its Ophthalmic Division, covering specific territories, to Sunways (India) Private Limited for Rs. 110 crores. This strategic divestment allows the company to focus on core therapeutic areas.
Apr 30 2026 18:04:00
Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
Indoco Remedies' Board approved the divestment of its Ophthalmic Division in India and other territories to Sunways (India) Private Limited via a slump sale for Rs. 110 crore. This strategic move aims to sharpen the company's focus on its core therapeutic segments.
Apr 30 2026 18:04:00
Indoco Remedies Limited
Indoco Remedies' Chhatrapati Sambaji Nagar testing facility successfully completed a U.S. FDA Pre-Approval Inspection with zero form 483 observations. This positive outcome indicates strong compliance, which is crucial for maintaining and expanding its market reach for pharmaceutical products.
Apr 13 2026 18:04:00
Indoco Remedies Ltd - 532612 - Update On The Company''s Testing Facility At Chhatrapati Sambaji Nagar - Aurangabad
Indoco Remedies announced its Chhatrapati Sambaji Nagar (Aurangabad) testing facility successfully completed a US FDA Pre-Approval Inspection (PAI). The inspection, held from April 08-10, 2026, concluded with zero Form 483 observations, indicating full compliance and readiness for future product approvals.
Apr 13 2026 18:04:00
Read More